Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haemophilus influenzae bacterial lysate
- Development stage
- Unknown
- Lead developer
- Lallemand Pharma
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Haemophilus influenzae bacterial lysate is an immunostimulating agent derived from the lysis of *Haemophilus influenzae* bacteria. It is primarily used for the prevention and treatment of recurrent lower respiratory tract infections, particularly in patients prone to chronic bronchitis or recurrent pneumonia. The lysate acts by stimulating the mucosal immune system, increasing the production of secretory IgA and activating innate immune cells such as macrophages and T-lymphocytes, thereby enhancing the body's natural defense mechanisms against subsequent infections by the same pathogen. It is developed and marketed by Laboratorio Farmaceutico S.I.T. as a monovalent bacterial preparation.
- Brand names
- Haemophilus SIT
- Other names
- Haemophilus influenzae lysate
02
Targets
sIgA (Secretory immunoglobulin A)
Beyond the preview
Go deeper on haemophilus influenzae bacterial lysate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haemophilus influenzae bacterial lysate.